Leukadherin-1

Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling[1][2][3].

Product Specifications

CAS Number

[344897-95-6]

UNSPSC

12352005

Hazard Statement

H302, H410

Target

Complement System; Integrin

Type

Reference compound

Related Pathways

Cytoskeleton; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Leukadherin-1.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)C=C1

Molecular Formula

C22H15NO4S2

Molecular Weight

421.49

Precautions

H302, H410

References & Citations

[1]Jagarapu J, et al. Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol. 2015;53 (6) :793-801.|[2]Maiguel D, et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011;4 (189) :ra57.|[3]Roberts AL, et al. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. Clin Exp Immunol. 2016;185 (3) :361-371.